Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505329 | 0.83 | MAPT (0.44) | LMNATDP1ALDH1A1KDM4EMAPT | |
| SCHEMBL2618837 | 0.82 | LMNA (0.39) | LMNAALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6410382 | 0.82 | TDP1 (0.43) | TDP1ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL21101990 | 0.79 | HTT (0.38) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1MAPK1 | |
| SCHEMBL6402838 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTMAPK1HSD17B10 | |
| SCHEMBL12994623 | 0.75 | MAPT (0.48) | LMNATDP1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL12228137 | 0.72 | POLB (0.51) | LMNAALDH1A1MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL529539 | 0.72 | MAPT (0.44) | LMNATDP1ALDH1A1KDM4EMAPT | |
| SCHEMBL528260 | 0.71 | ALDH1A1 (0.39) | LMNAALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL11224479 | 0.71 | SMN1; SMN2 (0.58) | LMNAALDH1A1KDM4ESMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| WO-2019111225-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NON‑ALCOHOLIC STEATOHEPATITIS | AVALIV THERAPEUTICS (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CRBN, CSNK2A1, CSNK2A2 | LMNA 2513/4885TDP1 3260/4885ALDH1A1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.